1. Merzon, E., Grossman, J., Vinker, S., Merhasin, I., Levit, S. and Golan‐Cohen, A., 2020. Factors associated with withdrawal from insulin pump therapy: a large‐population‐based study.
Diabetes/Metabolism Research and Reviews.
2. Levit, S., Giveon, S., Musin, I., Barnea, R., Korek-Abadi, I., Levit, V., Ryder, D. and Ryder, C.H., Continuous glucose monitoring-proved hypoglycemia in sodium-glucose co-transporter-2 inhibitors-treated type 2 diabetes patients: a link to ketosis development. Pharmacy Formulas, N1, p. 62-69, 2019.
3. S. Levit, G. Ginossar, A. Zivony, R. Barnea, I. KorekAbadi5, R. Chen Hanna. CGM MAY SERVE AS A ''GOLD STANDARD'' TOOL,CONFIRMING METABOLIC RECOVERY AND RESTORATION OF FUNCTIONAL ABILITY AND SECRETION OF ENDOGENOUS INSULIN IN T2DMPATIENTS. DIABETES TECHNOLOGY & THERAPEUTICS
Volume 20, Supplement 1, 2018, p A-34. DOI: 10.1089/dia.2018.2525.abstracts
4. Levit, S. and Levit, V.M., 2016. Joseph Davidovich Levit–theoretician and practitioner of national endocrinology (90th birthday anniversary).
Diabetes mellitus,
19(5), pp.428-432.
5. Shmuel Levit, Shmuel Giveon, Yury I. Philippov , Ivan PanchevDomuschiev , Amir Zivony.Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room? Diabetes Mellitus. 2016;19(4):341-349.
doi:
10.14341/DM7077 .
6. Shmuel Levit, Julio Wainstein, Royi Barnea; Ifat Korek-Abadi. CGM-proved hypoglycemia in SGLT2-i treated Type 2 Diabetes Patients. A link to Ketoacidosis? Abstracts from ATTD 2017 10th International Conference on Advanced Technologies & Treatments for Diabetes Paris, France—February 15–18, 2017. Diabetes Technology & Therapeutics, 19(S1), pp.A-1.
7. Shmuel Levit; Shmuel Giveon; Gideon Ginossar;Julio Weinstein; Yoel Toledano. OCCURRENCE OF HYPOGLYCEMIA IN TYPE 2 DIABETES PATIENTS IN A PERSPECTIVE OF A NEW THERAPEUTIC PARADIGM. DIABETES TECHNOLOGY & THERAPEUTICS VOLUME 18, (SUPPLEMENT 1, 2016) FEBRUARY 2016; DOI:
10.1089/dia.2016.2525 8. Levit, S., 2015, February. ARE INSULIN PUMPS A VIABLE TREATMENT OPTION IN TYPE 2 DIABETES?. In DIABETES TECHNOLOGY & THERAPEUTICS (Vol. 17, pp. A61-A61). 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA: MARY ANN LIEBERT, INC.
9. Shmuel Levit, Julio Weinstein; Mona Boaz; Maria Weichman; Joseph Azuri; Yossi Manistesky; Yoel Toledano; Gideon Ginossar.Can we predict the success of combined GLP-1 – insulin therapy? A proof- of- concept. The National Diabetes Congress 2015, At Tel Aviv; Israel;
DOI: 10.13140/RG.2.1.1782.4726 10. Insulin/weight ratio may serve as a predictor of success during insulin pump therapy in type 2 diabetes patients: a proof-of-concept study. Levit S., Philippov Y.I., Cohen O., Weichman M., Azuri J., ManisterskyY., Levit V.
Diabetes Mellitus, 2015;(1):70-77; DOI:
http://dx.doi.org/10.14341/DM2015170-77 11. S. Levit, Julio Weinstein; Mona Boaz; Maria Weichman; Joseph Azuri; Yossi Manistersky
. Diabetes Type 2 is Reversible and Curable. A long - term experience of using GLP-1 analogues in T2DM persons. A proof- of- concept.
The First Scientific Conference of Assuta-Maccabi. 18/12/2014 .Tel – Aviv. Israel.
12. S. Levit . Disease maintenance vs. disease cure: Gravicentric concept in Type 2 DM. The Joint Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis And Israel Diabetes Association. September 3-4, 2014, Tel – Aviv, Israel. Book of abstracts, p.46.
13. S. Levit ., Cohen O, Azuri J, Manistersky Y, Levit V, Weichman M. Insulin/Weight Ratio reduction during insulin pump therapy may serve as a predictor of success in Type 2 Diabetes.: a proof- of- concept. The Joint Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis And Israel Diabetes Association. September 3-4, 2014, Tel – Aviv, Israel. Book of abstracts, p. 47 .
14. Zohar Landau, David Klonoff, Irina Nayberg, Dmitry Feldman, Shmuel Boris Levit, Dan Lender, Ofri Mosenzon, Itamar Raz, Julio Wainstein. Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using Insu Patch, a local heating device.doi: 10.1002/dmrr.2536
15. S. Levit. The place, efficacy and safety of Insulin Aspart 30 (BIAsp30) intype 2 diabetes. Expert Opinion. J o u r n al of Symptoms and Signs ,2014; Volume 3, Number 4., http://www.intermedcentral.hk/
16. S. Levit, Dzeranova L.K., Philippov Y.I.
The Gravicentric Concept in Type 2 Diabetes: practical implementation.Obesity and Metabolism, 3'2013. DOI:
http://dx.doi.org/10.14341/2071-8713-3865 17. S. Levit, Yu.I. Philippov, A. S. Gorelyshev. Type 2 diabetes mellitus: time to change the concept. Diabetes Mellitus. 2013 (1) ,91-102. Moscow. DOI:
http://dx.doi.org/10.14341/2072-0351-3603 18. S. Levit, Y. Toledano, J. Wainstein.
Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. International Journal of Clinical Practice, February 2011.
19. Shmuel (Boris) Levit.
Emergency situations and hospitalizations in the treatment of diabetic patients. Chapter in pan- Israeli Textbook of Diabetes. April 2007.
20. Ohad Cohen, Rachel Beery, Shmuel Levit, et al.
Scanning Electron Microscopy of Thyroid Cells Under Fully Hydrated Conditions—A Novel Technique for A Seasoned Procedure: A Brief Observation. THYROID. Volume 16, Number 10, 2006
21. Annat Jaffe, Hilel Vardi, Boris Levit, Yasmin Alkalay
. Diabetes in the Ethiopian Jewish community of Hadera: prevalence, atherosclerotic risk factors. Poster report. EASD. September 2001.
22. B.I. Levit.
Dynamics of clinical, immunological, biochemical data in the course of treatment of Autoimmune Thyroiditis with Levamisole and Aminocapronic Acid. The role of young scientists in Medical Help to the Population
. Chelyabinsk,1989, p 8.
23. P.D. Sinitsin,V.I. Lozhkina, B.I. Levit, I.M. Barghatova .
The use of echo- ophthalmoscope-21 for diagnosis of thyroid disease. Problems of endocr., 5,33,1987, Moscow, pp. 27-30.
24. I.D. Levit ,B.I. Levit. Treatment of autoimmune thyroiditis with Aminocapronic Acid. Questions of Endocrinology, Tallinn, 1984,pp. 100-101.
25. B.I. Levit. Dynamics of clinical, immunological, biochemical data in the course of autoimmune thyroiditis treated with Levamisole and Aminocapronic acid. The Third Whole -Union Congress of Endocrinology, Tashkent, 1989, pp. 495-496.
26. B.I. Levit.
Treatment of Autoimmune Thyroiditis with Levamisole as monotherapy and together with Thyroid Drugs. Clinics and treatment of internal diseases, Chelyabinsk, 1985, pp 60-63.
27. B.I. Levit.
Treatment of autoimmune thyroiditis with Levamisole. Questions of Endocr., Moscow, 1983, pp 106-111.
28. I.D. Levit, B.I. Levit.
Treatment of patients, suffering from Autoimmune Thyroiditis and Diabetes Mellitus with levamisole. Diabetes Mellitus, Questions of treatment and prophylaxis. V. 58, Kazan, 1982,pp. 54-57.